Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Lonza Group AG
  6. Summary
    LONN   CH0013841017

LONZA GROUP AG

(LONN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
06/16/2021 06/17/2021 06/18/2021 06/21/2021 06/22/2021 Date
665.6(c) 658(c) 652(c) 644.2(c) 648.8(c) Last
145 946 314 389 548 383 276 460 185 517 Volume
+0.82% -1.14% -0.91% -1.20% +0.71% Change
More quotes
Estimated financial data (e)
Sales 2021 5 053 M 5 495 M 5 495 M
Net income 2021 835 M 908 M 908 M
Net Debt 2021 1 197 M 1 302 M 1 302 M
P/E ratio 2021 57,2x
Yield 2021 0,48%
Sales 2022 5 567 M 6 053 M 6 053 M
Net income 2022 973 M 1 058 M 1 058 M
Net Debt 2022 998 M 1 086 M 1 086 M
P/E ratio 2022 49,0x
Yield 2022 0,52%
Capitalization 48 195 M 52 367 M 52 402 M
EV / Sales 2021 9,77x
EV / Sales 2022 8,84x
Nbr of Employees 16 540
Free-Float 99,6%
More Financials
Company
Lonza Group AG (Lonza) is a Switzerland-based holding company and a supplier to the pharmaceutical, healthcare and life science industries. The Company's offerings include custom development and manufacturing of drugs and drug delivery systems, as well as development of anti-microbial solutions for commercial applications. The Company divides its activities into two segments: Pharma&Biotech and Specialty Ingredients. 
More about the company
Ratings of Lonza Group AG
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
A-
More Ratings
All news about LONZA GROUP AG
06/22LONZA  : European Commission OKs Bain, Cinven's Acquisition of Lonza's Specialty..
MT
06/21LONZA  : SelectImmune Pharma Seek to Develop Immunotherapeutic Drug
MT
06/21LONZA  : SelectImmune Collaborates with Lonza to Develop an Immunotherapeutic Dr..
PU
06/21LONZA  : SelectImmune Pharma Collaborates with Lonza to Develop an Immunotherape..
AQ
06/20LONZA  : to Develop, Manufacture ValenzaBio's Antibody For Autoimmune Diseases
MT
06/18LONZA  : and ValenzaBio Enter Manufacturing Agreement to Rapidly Advance VB421, ..
PU
06/15LONZA  : AlphaValue/Baader Europe Lifts Price Target on Lonza Group, Downgrades ..
MT
06/15AstraZeneca antibody cocktail fails to prevent COVID-19 in large trial
RE
06/11ANALYST RECOMMENDATIONS : Brown-Forman, Casey's General Stores, GameStop, Reckit..
06/10LONZA  : Research Partners Lifts Price Target on Lonza Group, Maintains Buy Reco..
MT
06/08ANALYST RECOMMENDATIONS : Amgen, Biogen, Halfords, J Sainsbury, Uber...
06/08European shares at fresh peaks as travel, real estate stocks lead
RE
06/02Health Care Down As Traders Rotate Into Sectors Linked To Reopening -- Health..
DJ
06/02MODERNA  : Lonza and Moderna Announce Further Collaboration For Drug Substance M..
AQ
06/02LONZA  : and Moderna to Set Up a New Production Line in Geleen, Netherlands
MT
More news
News in other languages on LONZA GROUP AG
06/21Aktien Schweiz pirschen sich wieder an die 12.000-Punktemarke heran
06/21Lonza coopère avec SelectImmune pour le développement de candidats
06/21Lonza und SelectImmune kooperieren bei Entwicklung von Immuntherapie-Proteine..
06/18Lonza et Valenzabio concluent un accord de développement et production
06/18Lonza und ValenzaBio unterzeichnen Entwicklungs- und Produktionsvereinbarung
More news
Analyst Recommendations on LONZA GROUP AG
More recommendations
Chart LONZA GROUP AG
Duration : Period :
Lonza Group AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends LONZA GROUP AG
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Last Close Price 648,80 CHF
Average target price 685,14 CHF
Spread / Average Target 5,60%
EPS Revisions
Managers and Directors
NameTitle
Pierre-Alain Ruffieux Chief Executive Officer
Rodolfo Savitzky Chief Financial Officer
Albert M. Baehny Chairman
Werner J. Bauer Independent Director
Barbara May Richmond No-Executive Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
LONZA GROUP AG14.06%52 367
MODERNA, INC.111.89%83 614
IQVIA HOLDINGS INC.35.88%46 660
CELLTRION, INC.-24.79%33 793
SEAGEN INC.-9.40%28 728
HANGZHOU TIGERMED CONSULTING CO., LTD14.49%24 977